Myotonic Dystrophy Drug Market

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
Myotonic Dystrophy Drug Market contains market size and forecasts of Myotonic Dystrophy Drug in global, including the following market information:
Global Myotonic Dystrophy Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Myotonic Dystrophy Drug Market Sales, 2017-2022, 2023-2028, (K Unit)
Global top five Myotonic Dystrophy Drug companies in 2021 (%)
The global Myotonic Dystrophy Drug market was valued at 43 million in 2021 and is projected to reach US$ 67 million by 2028, at a CAGR of 6.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Sodium Channel Blocker Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Myotonic Dystrophy Drug include Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, Sun Pharma and Mallinckrodt, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Myotonic Dystrophy Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myotonic Dystrophy Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Myotonic Dystrophy Drug Market Segment Percentages, by Type, 2021 (%)
Sodium Channel Blocker
Tricyclic Antidepressant
Other
Global Myotonic Dystrophy Drug Market, by Distribution Channel, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Myotonic Dystrophy Drug Market Segment Percentages, by Distribution Channel, 2021 (%)
Hospital Pharmacy
Retail Pharmacy
Other
Global Myotonic Dystrophy Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Unit)
Global Myotonic Dystrophy Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Myotonic Dystrophy Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Myotonic Dystrophy Drug revenues share in global market, 2021 (%)
Key companies Myotonic Dystrophy Drug sales in global market, 2017-2022 (Estimated), (K Unit)
Key companies Myotonic Dystrophy Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lupin
Teva
ANI Pharmaceuticals
Mylan
Novartis
Sun Pharma
Mallinckrodt